GLAXO — GlaxoSmithKline Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- IN₹482.77bn
- IN₹461.02bn
- IN₹34.54bn
Annual cashflow statement for GlaxoSmithKline Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 6,472 | 7,231 | 7,675 | 8,374 | 9,598 |
| Depreciation | |||||
| Non-Cash Items | -976 | -1,233 | -243 | -1,085 | -2,543 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1,418 | -1,012 | -6.37 | -3,105 | -1,932 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 4,905 | 5,779 | 8,107 | 4,842 | 5,820 |
| Capital Expenditures | -1,584 | -442 | -346 | -440 | -312 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1,015 | 4,628 | -3,709 | 8,519 | 399 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -568 | 4,186 | -4,055 | 8,079 | 87.1 |
| Financing Cash Flow Items | -738 | -35.3 | -19.9 | -9.55 | -18 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -4,276 | -6,961 | -5,242 | -15,433 | -5,615 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 60.3 | 3,004 | -1,190 | -2,512 | 292 |